India has approved two vaccines against COVID-19 -- Covishield, manufactured by the SII, and the indigenously-developed Covaxin of Bharat Biotech. (Photo | EPS) 
India

Centre places new purchase order with Serum Institute of India for 10 crore doses of Covishield vaccine

The cost of the 10 crore doses would be borne by the health ministry under the budgetary allocation for the purpose.

PTI

NEW DELHI: The Centre has placed a new purchase order with the Serum Institute of India (SII) for the supply of 10 crore doses of the Oxford-AstraZeneca COVID-19 vaccine, Covishield, each costing Rs 157.50, including GST, according to official sources.

The HLL Lifecare Limited, a public sector undertaking, has issued the supply order on behalf of the Union health ministry on March 12 in the name of Prakash Kumar Singh, Director, Government and Regulatory Affairs at the Pune-based SII.

The cost of the 10 crore doses would be borne by the health ministry under the budgetary allocation for the purpose.

The expenditure for the earlier orders of the vaccines was funded through the PM Cares Fund, the sources said.

India has approved two vaccines against COVID-19 -- Covishield, manufactured by the SII, and the indigenously-developed Covaxin of Bharat Biotech -- for restricted emergency use in the country.

ALSO WATCH:​

Why the additional declaration linked to Form 6 is facing a legal challenge

SP-Congress alliance faces fresh strain as Akhilesh skips INDIA bloc meet over UP seat-sharing talks

Rahul Gandhi tells CWC to continue 'resistance' against 'match-fixing' of polls through EVM, voters list

Assam Rifles jawan killed in militant attack in Arunachal; security forces intensify ops to arrest killers

SC slams medicine pricing, calls cancer drug’s 10-fold MRP markup ‘carnage’